OCULAR THERAPEUTIX, INC.
Last · NASDAQ$7.20-0.04 (-0.55%)close · yahoo · 12h ago
Market cap$1.58B219.6M sh
P/E · TTM-5.1fwd -4.9 · eps -1.40 · loss
Beta0.99vs S&P 500
Div yield0.00%annual · TTM
52w range
$6.23$16.44
Volume2.2Msession
| Revenue | $63.7M |
|---|---|
| Operating income | $-171.8M |
| Net income | $-193.5M |
| Free cash flow | $-136.0M |
| Operating margin | -269.6% |
| Net margin | -303.7% |
| Return on equity | -61.4% |
| Period | 2024 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2025-03-03
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Medium
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 52.0%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -303.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -211.3%
- Cash Runway Medium — Cash runway ~2.9 years
- Accumulated Deficit High — Accumulated deficit / equity 283%
- Rd Intensity High — R&D/Revenue 200.3%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.35
Est. revenue
14.3M
Press & signals
- GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans